Trump’s Executive Order on Drug Pricing

On Tuesday, President Donald Trump signed an executive order aimed at reshaping prescription drug pricing in the United States, targeting what the pharmaceutical industry has dubbed the “pill penalty” embedded in President Joe Biden’s Inflation Reduction Act (IRA). The executive order, released by The White House, seeks to align the treatment of small molecule prescription drugs—commonly taken in pill or capsule form—with that of more complex biologic drugs under the Medicare Drug Price Negotiation Program. This move has sparked heated debate, with supporters arguing it fosters innovation and critics warning it prioritizes pharmaceutical profits over patient affordability. 

Understanding the Pill Penalty 

The “pill penalty” refers to a provision in the IRA that allows the government to negotiate prices for biologic drugs after 13 years on the market, but only after 9 years for small molecule drugs. Small molecule drugs, often cheaper and used to treat larger patient populations, are critical to addressing widespread conditions like diabetes, hypertension, and cholesterol. Biologics, by contrast, are typically more expensive, complex, and indicated for rarer diseases. 

The pharmaceutical industry, led by the Pharmaceutical Research and Manufacturers of America (PhRMA), has argued that this four-year discrepancy disincentivizes investment in small molecule drugs. Stephen Ubl, PhRMA’s president and CEO, emphasized this point in discussions with J.P. Morgan analysts in 2023, stating that the shorter timeline for price negotiations under Medicare stifles private capital investment in research and development (R&D) for these drugs. A PhRMA survey revealed that 63% of its members were shifting focus toward biologics due to the IRA’s structure, potentially limiting innovation in more accessible, widely used medications. 

Trump’s executive order directs the Secretary of Health and Human Services, Robert F. Kennedy Jr., to collaborate with Congress to extend the negotiation timeline for small molecule drugs to 13 years, aligning it with biologics. The order argues that this change will correct a distortion that pushes investment toward costly biologics, ultimately benefiting patients by encouraging the development of affordable drugs for common conditions. 

The Executive Order’s Broader Goals 

While the alignment of negotiation timelines is the centerpiece, the executive order also outlines additional steps to reduce drug prices, though specifics remain vague. It instructs Kennedy to propose initial price applicability for 2028 and establish manufacturer maximum fair prices for 2026, 2027, and 2028 within 60 days, while seeking public comment. The order emphasizes that these measures will deliver greater cost savings than those achieved under the Biden administration’s implementation of the Medicare Drug Price Negotiation Program. 

The White House frames the executive order as a continuation of Trump’s earlier efforts to lower drug costs, accusing the Biden administration of reversing or neglecting prior initiatives. It criticizes the IRA’s negotiation program as “administratively complex and expensive,” claiming it has produced lower-than-projected savings. The first round of Medicare negotiations under the IRA achieved an average 22% price reduction on 10 high-cost drugs, projected to save taxpayers $6 billion. However, the Trump administration argues that more aggressive negotiations and structural reforms could yield even greater benefits for patients and Medicare beneficiaries. 

Why This Matters 

The debate over the pill penalty is more than a technical dispute—it’s a clash of priorities in healthcare policy. Small molecule drugs are a cornerstone of modern medicine, offering cost-effective solutions for millions of patients. By shortening the period before price negotiations, the IRA aimed to make these drugs more affordable sooner. However, pharmaceutical companies argue that this approach undercuts the financial incentive to innovate, as the high costs of R&D require a longer runway to recoup investments. 

The executive order’s push to extend the negotiation timeline for small molecule drugs could encourage investment in this critical area, potentially leading to new treatments for widespread conditions. However, critics like Merith Basey, executive director of Patients For Affordable Drugs, argue that the change is a “clear giveaway to Big Pharma.” Basey contends that delaying negotiations by four years allows drug companies to maintain high prices longer, exacerbating the affordability crisis for one in three Americans who struggle to pay for prescriptions. She dismisses claims that the change supports innovation, asserting it’s primarily about protecting “exorbitant profits.” 

The executive order’s reliance on congressional approval adds another layer of complexity. The Medicare Drug Price Negotiation Program is enshrined in legislation, meaning Trump cannot unilaterally implement the proposed changes. Kennedy’s mandate to work with Congress will test the administration’s ability to navigate a polarized legislative landscape, where pharmaceutical lobbying and patient advocacy groups are likely to clash. 

Stakeholder Reactions 

The executive order has elicited polarized responses from stakeholders. Cynthia Fisher, founder and chair of Patient Rights Advocate, praised Trump’s actions, arguing that they will deliver savings to American families and enhance economic competitiveness through fair market pricing. She views the order, alongside Trump’s earlier executive order on healthcare price transparency, as a step toward reducing overcharges in drugs and healthcare. 

On the other hand, Basey acknowledged the administration’s recognition of the urgency to address high drug prices, aligning with public demand. She highlighted the IRA’s initial success in reducing prices and urged the administration to pursue more aggressive negotiations in future rounds. However, she warned that extending the negotiation timeline for small molecule drugs undermines these efforts, prioritizing industry interests over patient needs. 

PhRMA and its members, while not directly quoted in response to the executive order, have consistently advocated for changes to the IRA’s structure. The organization’s earlier warnings about the pill penalty suggest that the executive order aligns with its goals, potentially reversing the shift toward biologics and encouraging renewed investment in small molecule drugs. 

The Larger Trend 

The executive order is part of a broader push by the Trump administration to reshape healthcare policy, building on initiatives like price transparency and drug cost reduction. It reflects ongoing tensions between fostering pharmaceutical innovation and ensuring affordable access to medications. The IRA’s negotiation program, while controversial, marked a significant step toward government intervention in drug pricing, a trend that continues under Trump’s order, albeit with different priorities. 

The focus on small molecule drugs also highlights the evolving landscape of pharmaceutical R&D. As biologics dominate investment due to their complexity and profitability, policies that influence the balance between biologics and small molecules will shape the future of drug development. The outcome of this debate could determine whether patients gain access to innovative, affordable treatments or face prolonged periods of high prices. 

Challenges and Next Steps 

Implementing the executive order’s vision will require overcoming significant hurdles. Congressional approval is far from guaranteed, given the competing interests of pharmaceutical companies, patient advocates, and budget-conscious lawmakers. Kennedy’s role in proposing regulations and engaging stakeholders will be critical, particularly as public comment periods and legislative negotiations unfold. 

Moreover, the executive order’s claim of delivering greater savings than the IRA remains untested. The Biden administration’s program, despite its complexities, has demonstrated tangible results. The Trump administration will need to provide concrete evidence that its reforms can outperform these benchmarks without increasing overall costs to Medicare or beneficiaries. 

President Trump’s executive order on prescription drug pricing is a bold attempt to address the so-called pill penalty and rebalance incentives in pharmaceutical innovation. By seeking to align negotiation timelines for small molecule and biologic drugs, the order aims to foster investment in affordable, widely used medications. However, critics argue that it risks prioritizing industry profits over patient affordability, highlighting the delicate balance between innovation and access. 

As the administration works with Congress to enact these changes, the outcome will have far-reaching implications for patients, providers, and the pharmaceutical industry. Whether the executive order delivers on its promise of lower costs and greater innovation remains to be seen, but it has reignited a critical conversation about the future of drug pricing in America.